October 14, 2021
Dr. Mitchell Levine
Chair, Patented Medicine Prices Review Board (PMPRB)
333 Laurier Avenue West, Suite 1400
Ottawa ON, K1P 1C1
Subject: Request to postpone decision on July 15, 2021 PMPRB Guidelines changes
Dear Dr. Levine,
As leaders of eight of Canada’s provincial health and life sciences organizations, we are writing to express concerns about the PMPRB’s impending decision on the above-noted proposed Guidelines changes. We strongly believe you should postpone any decisions related to this initiative for several important reasons.
First, it would be untimely to take a final decision on these changes before the opening of the 44th parliament, following the recent federal election. This initiative is part of a major change to Canada’s pharmaceutical pricing environment, and it merits careful assessment by political leaders, many of whom ran on a mandate to help bolster our health system, life sciences research and manufacturing capacity to finish the fight against COVID and build back better. It is worth noting that this initiative also runs contrary to the 5th pillar of the Federal Biomanufacturing and Life Sciences Strategy, which strives to enable innovation by ensuring “world class regulation.” We strongly recommend waiting until new ministers and other political appointments have been made, mandate letters have been issued, and decision-makers have been briefed on this issue before moving forward.
Read the full letter here.